Antiviral gene therapy

Handbook of Experimental Pharmacology

Volumn 189, Issue , 2009, Pages 265-297

  Von Laer, D ^a   Baum, C ^b   Protzer, U ^b  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY; C46 PROTEIN; CD4 ANTIGEN; CD4ZETA; COMPLEMENTARY RNA; CYTOKINE; EPSTEIN BARR VIRUS ANTIGEN 1; GAG PROTEIN; GLYCOPROTEIN GP 41 ANTIBODY; HYBRID PROTEIN; INTERFERON; MAC46 PROTEIN; MONOCLONAL ANTIBODY 2F5; NEUTRALIZING ANTIBODY; PROTEIN SAM68; REV PROTEIN; REVM10; RIBOZYME; SHORT HAIRPIN RNA; TDREV PROTEIN; TDTAT PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS RECEPTOR; VIRUS RNA; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENO ASSOCIATED VIRUS; ADENOVIRUS; ADOPTIVE TRANSFER; BYSTANDER EFFECT; CLINICAL TRIAL; DNA MODIFICATION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENOTOXICITY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; INNATE IMMUNITY; LIFE CYCLE; LYMPHOMA; NONHUMAN; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; REVIEW; STEM CELL; T LYMPHOCYTE; TARGET CELL; VIRUS GENE; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; CHEMISTRY; DRUG EFFECT; GENETIC MARKER; GENETICS; IMMUNITY; IMMUNOLOGY; PHYSIOLOGY; VIRUS;

ADOPTIVE TRANSFER; ANIMALS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENETIC MARKERS; GENETIC VECTORS; HUMANS; IMMUNITY; T-LYMPHOCYTES; VIRUS DISEASES; VIRUS REPLICATION; VIRUSES;

EID: 61549106329     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-79086-0_10     Document Type: Review

References (174)

1. Abken H, Hombach A, Heuser C (2003) Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity. Curr Pharm Des 9:1992-2001
2. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG, Bordignon C (2002a) Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296:2410-2413
3. Aiuti A, Vai S, Mortellaro A, Casorati G, Ficara F, Andolfi G, Ferrari G, Tabucchi A, Carlucci F, Ochs HD, Notarangelo LD, Roncarolo MG, Bordignon C (2002b) Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 8:423-425
4. Amado RG, Mitsuyasu RT, Rosenblatt JD, Ngok FK, Bakker A, Cole S, Chorn N, Lin LS, Bristol G, Boyd MP, MacPherson JL, Fanning GC, Todd AV, Ely JA, Zack JA, Symonds GP (2004) Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther 15:251-262
5. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, Havlir DV, Richman DD, Waters A, Easterbrook P, McMichael AJ, Rowland-Jones SL (2000) HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 192:63-75
6. Bahner I, Kearns K, Hao QL, Smogorzewska EM, Kohn DB (1996) Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture. J Virol 70:4352-4360
7. Bai J, Gorantla S, Banda N, Cagnon L, Rossi J, Akkina R (2000) Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther 1:244-254
8. Bai J, Rossi J, Akkina R (2001) Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy. AIDS Res Hum Retroviruses 17:385-399
9. Bai J, Sui J, Zhu RY, Tallarico AS, Gennari F, Zhang D, Marasco WA (2003) Inhibition of Tatmediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem 278:1433-1442
10. Baltimore D (1988) Gene therapy. Intracellular immunization. Nature 335:395-396
11. Basta S, Stoessel R, Basler M, van den Broek M, Groettrup M (2005) Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J Immunol 175:796-805
12. Baum C (2007) Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol 14:337-342
13. Beterams G, Nassal M (2001) Significant interference with hepatitis B virus replication by a corenuclease fusion protein. J Biol Chem 276:8875-8883
14. Beterams G, Bottcher B, Nassal M (2000) Packaging of up to 240 subunits of a 17 kDa nuclease into the interior of recombinant hepatitis B virus capsids. FEBS Lett 481:169-176
15. Bevec D, Jaksche H, Oft M, Wohl T, Himmelspach M, Pacher A, Schebesta M, Koettnitz K, Dobrovnik M, Csonga R, Lottspeich F, Hauber J (1996) Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A. Science 271:1858-1860
16. Bohne F, Protzer U (2007) Adoptive T-cell therapy as a therapeutic option for chronic hepatitis B. J Viral Hepat 14 Suppl 1:45-50
17. Bohne F, Chmielewski M, Ebert G, Wiegmann K, Kurschner T, Schulze A, Urban S, Kronke M, Abken H, Protzer U (2008) T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 134:239-247
18. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, Mazzolari E, Maggioni D, Rossi C, Servida P (1995) Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270:470-475
19. BouHamdan M, Strayer DS, Wei D, Mukhtar M, Duan LX, Hoxie J, Pomerantz RJ (2001) Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4. Gene Ther 8:408-418
20. Buchschacher GL Jr, Wong-Staal F (2001) Approaches to gene therapy for human immunodeficiency virus infection. Hum Gene Ther 12:1013-1019
21. Buchschacher GL Jr, Wong-Staal F, San Jose E, Munoz-Fernandez MA, Alarcon B (2001) Approaches to gene therapy for human immunodeficiency virus infection. Hum Gene Ther 12:1013-1019
22. Bukovsky AA, Song JP, Naldini L (1999) Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol 73:7087-7092
23. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-672
24. Chaloin L, Lehmann MJ, Sczakiel G, Restle T (2002) Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res 30:4001-4008
25. Chamoto K, Tsuji T, Funamoto H, Kosaka A, Matsuzaki J, Sato T, Abe H, Fujio K, Yamamoto K, Kitamura T, Takeshima T, Togashi Y, Nishimura T (2004) Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res 64:386-390
26. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S (2005) Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23:8942-8949
27. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD (2000) Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 74:8207-8212
28. Cornetta K, Croop J, Dropcho E, Abonour R, Kieran MW, Kreissman S, Reeves L, Erickson LC, Williams DA (2006) A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase. Cancer Gene Ther 13:886-895
29. Cremer I, Vieillard V, De Maeyer E (2000) Retrovirally mediated IFN-beta transduction of macrophages induces resistance to HIV, correlated with up-regulation of RANTES production and down-regulation of C-C chemokine receptor-5 expression. J Immunol 164:1582-1587
30. Davis BM, Roth JC, Liu L, Xu-Welliver M, Pegg AE, Gerson SL (1999) Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: Implications for drug resistance gene therapy. Hum Gene Ther 10:2769-2778
31. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM (2002) A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 5:788-797
32. Dropulic B, Hermankova M, Pitha PM (1996) A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci USA 93:11103-11108
33. Duan L, Bagasra O, Laughlin MA, Oakes JW, Pomerantz RJ (1994) Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci USA 91:5075-5079
34. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002a) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854
35. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA (2002b) A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25:243-251
36. Dumortier J, Schonig K, Oberwinkler H, Low R, Giese T, Bujard H, Schirmacher P, Protzer U (2005) Liver-specific expression of interferon gamma following adenoviral gene transfer controls hepatitis B virus replication in mice. Gene Ther 12:668-677
37. Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan G, Kunert R, Baum C, Choi I, Alexandrov A, von Laer D (2004) Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 78:568-575
38. Ehrhardt A, Kay MA (2002) A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 99:3923-3930
39. Ehrhardt A, Xu H, Dillow AM, Bellinger DA, Nichols TC, Kay MA (2003) A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood 102:2403-2411
40. Engels B, UckertW(2007) Redirecting T lymphocyte specificity by T cell receptor gene transfer-a new era for immunotherapy. Mol Aspects Med 28:115-142
41. Feng Y, Leavitt M, Tritz R, Duarte E, Kang D, Mamounas M, Gilles P, Wong-Staal F, Kennedy S, Merson J, Yu M, Barber JR (2000) Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. Virology 276:271-278
42. Ferrand C, Robinet E, Contassot E, Certoux JM, Lim A, Herve P, Tiberghien P (2000) Retrovirusmediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire. Hum Gene Ther 11:1151-1164
43. Fiedler M, Rodicker F, Salucci V, Lu M, Aurisicchio L, Dahmen U, Jun L, Dirsch O, Putzer BM, Palombo F, Roggendorf M (2004) Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-alpha) and IFN-gamma: IFN-alpha but not IFN-gamma reduces woodchuck hepatitis virus replication in chronic infection in vivo. J Virol 78:10111-10121
44. Fraisier C, Abraham DA, van Oijen M, Cunliffe V, Irvine A, Craig R, Dzierzak EA (1998) Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins. Gene Ther 5:946-954
45. Gao GP, Lu Y, Sun X, Johnston J, Calcedo R, Grant R, Wilson JM (2006) High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes. J Virol 80:6192-6194
46. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP (2006) Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 6:383-393
47. Gay W, Lauret E, Boson B, Larghero J, Matheux F, Peyramaure S, Rousseau V, Dormont D, De Maeyer E, Le Grand R (2004) Low autocrine interferon beta production as a gene therapy approach for AIDS: infusion of interferon beta-engineered lymphocytes in macaques chronically infected with SIVmac251. Retrovirology 1:29
48. Germain RN, Stefanova I (1999) The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol 17:467-522
49. Goldstein H, Pettoello-Mantovani M, Anderson CM, Cordelier P, Pomerantz RJ, Strayer DS (2002) Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue. J Infect Dis 185:1425-1430
50. Gong WD, Zhao Y, Yi J, Ding J, Liu J, Xue CF (2005) Anti-HBV activity of TRL mediated by recombinant adenovirus. World J Gastroenterol 11:2574-2578
51. Grimm D, Kay MA (2006) Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther 13:563-575
52. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV (1996) Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25-36
53. Habu Y, Miyano-Kurosaki N, Kitano M, Endo Y, Yukita M, Ohira S, Takaku H, Nashimoto M (2005) Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL. Nucleic Acids Res 33:235-243
54. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, KuisW, Leiva L, Cavazzana-Calvo M (2002) Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346:1185-1193
55. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A (2003a) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255-256
56. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP,Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, De Saint-Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-CalvoM(2003b) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415-419
57. Hess C, AltfeldM, Thomas SY, Addo MM, Rosenberg ES, Allen TM, Draenert R, Eldrige RL, van Lunzen J, Stellbrink HJ, Walker BD, Luster AD (2004) HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet 363:863-866
58. Hildinger M, Dittmar MT, Schult-Dietrich P, Fehse B, Schnierle BS, Thaler S, Stiegler G, Welker R, von Laer D (2001) Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol 75:3038-3042
59. Hotchkiss G, Maijgren-Steffensson C, Ahrlund-Richter L (2004) Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites. Mol Ther 10:172-180
60. Howe SJ, Mansour M, Brugman MH, Pike-Overzet K, de Ridder D, Hubank M, Staal FJ, Baum C, Kinnon C, Gaspar HB, Thrasher AJ (2008) Molecular analysis of a severe adverse event in the UK SCID-X1 gene therapy clinical trial. Mol Ther 16:S111
61. Hui CK, Lie A, Au WY, Leung YH, Ma SY, Cheung WW, Zhang HY, Chim CS, Kwong YL, Liang R, Lau GK (2005) A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 106:464-469
62. Jacquard AC, Nassal M, Pichoud C, Ren S, Schultz U, Guerret S, Chevallier M,Werle B, Peyrol S, Jamard C, Rimsky LT, Trepo C, Zoulim F (2004) Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 48:2683-2692
63. Joshi P, Prasad VR (2002) Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol 76:6545-6557
64. Joshi S, Van Brunschot A, Asad S, van der Elst I, Read SE, Bernstein A (1991) Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression. J Virol 65:5524-5530
65. Kang EM, De Witte M, Malech H, Morgan RA, Carter C, Leitman SF, Childs R, Barrett AJ, Little R, Tisdale JF (2002a) Gene therapy-based treatment for HIV-positive patients with malignancies. J Hematother Stem Cell Res 11:809-816
66. Kang EM, de Witte M, Malech H, Morgan RA, Phang S, Carter C, Leitman SF, Childs R, Barrett AJ, Little R, Tisdale JF (2002b) Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. Blood 99:698-701
67. Kawamura N, Ariga T, Ohtsu M, Kobayashi I, Yamada M, Tame A, Furuta H, Okano M, Egashira M, Niikawa N, Kobayashi K, Sakiyama Y (1999) In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient. J Immunol 163:2256-2261
68. Kim YK, Junn E, Park I, Lee Y, Kang C, Ahn JK (1999) Repression of hepatitis B virus X gene expression by hammerhead ribozymes. Biochem Biophys Res Commun 257:759-765
69. Kitamura Y, Ishikawa T, Okui N, Kobayashi N, Kanda T, Shimada T, Miyake K, Yoshiike K (1999) Inhibition of replication of HIV-1 at both early and late stages of the viral life cycle by single-chain antibody against viral integrase. J Acquir Immune Defic Syndr Hum Retrovirol 20:105-114
70. Kobinger GP, Borsetti A, Nie Z, Mercier J, Daniel N, Gottlinger HG, Cohen A (1998) Viriontargeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins. J Virol 72:5441-5448
71. Kohn DB, Bauer G, Rice CR, Rothschild JC, Carbonaro DA, Valdez P, Hao Q, Zhou C, Bahner I, Kearns K, Brody K, Fox S, Haden E, Wilson K, Salata C, Dolan C, Wetter C, Aguilar-Cordova E, Church J, Lee TC, Sullenger BA, Gallardo HF, Ungers GE, Gilboa E (1999) A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94:368-371
72. Kolb G, Reigadas S, Castanotto D, Faure A, Ventura M, Rossi JJ, Toulme JJ (2006) Endogenous expression of an anti-TAR aptamer reduces HIV-1 replication. RNA Biol 3:150-156
73. Korf M, Jarczak D, Beger C,Manns MP, KrugerM(2005) Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. J Hepatol 43:225-234
74. Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, Falk PM, Rosenthal J, Alvarnas J, Forman SJ (2005) Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 105:874-878
75. Kustikova OS, Fehse B, Düllmann J, Kamino K, von Neuhoff N, Schlegelberger B, Li Z, Baum C (2005) Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308:1171-1174
76. Lauret E, Vieillard V, Rousseau V, De Maeyer-Guignard J, De Maeyer E (1994) Exploring interferon beta for gene therapy of HIV infection. Res Immunol 145:674-677; discussion 677-678
77. Lee MT, Coburn GA, McClure MO, Cullen BR (2003) Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol 77:11964-11972
78. Lee SJ, Garza L, Yao J, Notkins AL, Zhou P (2004) A nonneutralizing anti-HIV-1 antibody turns into a neutralizing antibody when expressed on the surface of HIV-1-susceptible cells: A new way to fight HIV. J Immunol 173:4618-4626
79. Levine BL, Humeau LM, Boyer J, Macgregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, Bushman FD, Dropulic B, June CH (2006) Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 103:17372-17377
80. Levy-Mintz P, Duan L, Zhang H, Hu B, Dornadula G, Zhu M, Kulkosky J, Bizub-Bender D, Skalka AM, Pomerantz RJ (1996) Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase [published erratum appears in J Virol 1998 Apr;72(4):3505-6]. J Virol 70:8821-8832
81. Li X, Gervaix A, Kang D, Law P, Spector SA, Ho AD,Wong-Staal F (1998a) Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studies. Gene Ther 5:233-239
82. Li XL, Blackford JA, Hassel BA (1998b) RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J Virol 72:2752-2759
83. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kuhlcke K, Eckert HG, Fehse B, Baum C (2002) Murine leukemia induced by retroviral gene marking. Science 296:497
84. Lieberman J, Skolnik PR, Parkerson GR 3rd, Fabry JA, Landry B, Bethel J, Kagan J (1997) Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood 90:2196-2206
85. Lim BK, Choi JH, Nam JH, Gil CO, Shin JO, Yun SH, Kim DK, Jeon ES (2006) Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis. Cardiovasc Res 71:517-526
86. Lohrengel S, Hermann F, Hagmann I, Oberwinkler H, Scrivano L, Hoffmann C, von Laer D, Dittmar MT (2005) Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J Virol 79:10237-10246
87. Lund O, Lund OS, Gram G, Nielsen SD, Schonning K, Nielsen JO, Hansen JE, Mosekilde E (1997) Gene therapy of T helper cells in HIV infection: mathematical model of the criteria for clinical effect. Bull Math Biol 59:725-745
88. Lunzen JV, Glaunsinger T, Stahmer I, Baehr VV, Baum C, Schilz A, Kuehlcke K, Naundorf S, Martinius H, Hermann F, Giroglou T, Newrzela S, Muller I, Brauer F, Brandenburg G, Alexandrov A, von Laer D (2007) Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 15:1024-1033
89. Macpherson JL, Boyd MP, Arndt AJ, Todd AV, Fanning GC, Ely JA, Elliott F, Knop A, Raponi M, Murray J, Gerlach W, Sun LQ, Penny R, Symonds GP, Carr A, Cooper DA (2005) Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients. J Gene Med 7:552-564
90. Malim MH, Hauber J, Fenrick R, Cullen BR (1988) Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature 335:181-183
91. Malim MH, Bohnlein S, Hauber J, Cullen BR (1989) Functional dissection of the HIV-1 Rev transactivator-derivation of a trans-dominant repressor of Rev function. Cell 58:205-214
92. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12:342-347
93. Masiero S, Del Vecchio C, Gavioli R, Mattiuzzo G, Cusi MG, Micheli L, Gennari F, Siccardi A, Marasco WA, Palu G, Parolin C (2005) T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther 12:299-310
94. Matskevich AA, Cordelier P, Strayer DS (2003) Conditional expression of IFN-alpha and IFNgamma activated by HBV as genetic therapy for hepatitis B. J Interferon Cytokine Res 23:709-721
95. Matsugami A, Kobayashi S, Ouhashi K, Uesugi S, Yamamoto R, Taira K, Nishikawa S, Kumar PK, Katahira M (2003) Structural basis of the highly efficient trapping of the HIV Tat protein by an RNA aptamer. Structure 11:533-545
96. Mautino MR, Morgan RA (2000) Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA. Hum Gene Ther 11:2025-2037
97. Melikyan GB, Egelhofer M, von Laer D (2006) Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J Virol 80:3249-3258
98. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, Van Baarle D, Kostense S, Miedema F, McLaughlin M, Ehler L, Metcalf J, Liu S, Connors M (2002) HIVspecific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3:1061-1068
99. Milsom MD, Fairbairn LJ (2004) Protection and selection for gene therapy in the hematopoietic system. J Gene Med 6:133-146
100. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA, Pennathur-Das R, Hege KM (2000) Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96:785-793
101. Modlich U, Bohne J, Schmidt M, von Kalle C, Knoss S, Schambach A, Baum C (2006) Cellculture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108:2545-2553
102. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, Sergi LS, Benedicenti F, Ambrosi A, Di Serio C, Doglioni C, von Kalle C, Naldini L (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24:687-696
103. Morgan RA, Baler-Bitterlich G, Ragheb JA,Wong-Staal F, Gallo RC, Anderson WF (1994) Further evaluation of soluble CD4 as an anti-HIV type 1 gene therapy: demonstration of protection of primary human peripheral blood lymphocytes from infection by HIV type 1. AIDS Res Hum Retroviruses 10:1507-1515
104. Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, Herpin B, Muul L, Zheng Z, Jagannatha S, Bunnell BA, Fellowes V, Metcalf JA, Stevens R, Baseler M, Leitman SF, Read EJ, Blaese RM, Lane HC (2005) Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther 16:1065-1074
105. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129
106. Nash KL, Alexander GJ, Lever AM (2005) Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes. J Viral Hepat 12:346-356
107. Nasimuzzaman M, Kuroda M, Dohno S, Yamamoto T, Iwatsuki K, Matsuzaki S, Mohammad R, Kumita W, Mizuguchi H, Hayakawa T, Nakamura H, Taguchi T, Wakiguchi H, Imai S (2005) Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1. Mol Ther 11:578-590
108. Neff T, Beard BC, Kiem HP (2006) Survival of the fittest: in vivo selection and stem cell gene therapy. Blood 107:1751-1760
109. Newrzela S, Cornils K, Li Z, Baum C, Brugman MH, Hartmann M, Hartmann S, Hansmann ML, Fehse B, von Laer D (2008) Resistance of mature T cells to oncogene transformation. Blood 112:2278-2286
110. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H (1996) Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 93:4398-4402
111. Okui N, Kobayashi N, Kitamura Y (1998) Production of uninfectious human immunodeficiency virus type 1 containing viral protein R fused to a single-chain antibody against viral integrase. J Virol 72:6960-6964
112. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kuhlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Luthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12:401-409
113. Pan WH, Xin P, Morrey JD, Clawson GA (2004) A self-processing ribozyme cassette: Utility against human papillomavirus 11 E6/E7 mRNA and hepatitis B virus. Mol Ther 9:596-606
114. Park J, Nadeau P, Zucali JR, Johnson CM,Mergia A (2005) Inhibition of simian immunodeficiency virus by foamy virus vectors expressing siRNAs. Virology 343:275-282
115. Parouchev A, Nguyen TH, Dagher I, Mainot S, Groyer-Picard MT, Branger J, Gonin P, Di Santo J, Franco D, Gras G, Weber A (2006) Efficient ex vivo gene transfer into non-human primate hepatocytes using HIV-1 derived lentiviral vectors. J Hepatol 45:99-107
116. Pearson L, Garcia J,Wu F, Modesti N, Nelson J, Gaynor R (1990) A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci USA 87:5079-5083
117. Podsakoff GM, Engel BC, Carbonaro DA, Choi C, Smogorzewska EM, Bauer G, Selander D, Csik S, Wilson K, Betts MR, Koup RA, Nabel GJ, Bishop K, King S, Schmidt M, von Kalle C, Church JA, Kohn DB (2005) Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther 12:77-86
118. Pomerantz RJ, Trono D, Feinberg MB, Baltimore D (1990) Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell 61:1271-1276
119. Poznansky MC, La Vecchio J, Silva-Arietta S, Porter-Brooks J, Brody K, Olszak IT, Adams GB, Ramstedt U, Marasco WA, Scadden DT (1999) Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat. Hum Gene Ther 10:2505-2514
120. Protzer U, Nassal M, Chiang PW, Kirschfink M, Schaller H (1999) Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection. Proc Natl Acad Sci USA 96:10818-10823
121. Puls RL, Emery S (2006) Therapeutic vaccination against HIV: current progress and future possibilities. Clin Sci (Lond) 110:59-71
122. Qin CF, Qin ED (2006) Capsid-targeted viral inactivation can destroy dengue 2 virus from within in vitro. Arch Virol 151:379-385
123. Ranga U, Woffendin C, Verma S, Xu L, June CH, Bishop DK, Nabel GJ (1998) Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci USA 95:1201-1206
124. Raper SE, Chirmule N, Lee FS,Wivel NA, Bagg A, Gao GP,Wilson JM, Batshaw ML (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:148-158
125. Re A, Cattaneo C, Michieli M, Casari S, SpinaM, RupoloM, Allione B, Nosari A, Schiantarelli C, Vigano M, Izzi I, Ferremi P, Lanfranchi A, Mazzuccato M, Carosi G, Tirelli U, Rossi G (2003) High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 21:4423-4427
126. Reddy TR, Xu W, Mau JK, Goodwin CD, Suhasini M, Tang H, Frimpong K, Rose DW, Wong-Staal F (1999) Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev. Nat Med 5:635-642
127. Rehermann B, Nascimbeni M (2005) Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5:215-229
128. Richardson JH, Child LA, Lever AM (1993) Packaging of human immunodeficiency virus type 1 RNA requires cis-acting sequences outside the 5' leader region. J Virol 67:3997-4005
129. Roberts MR, Qin L, Zhang D, Smith DH, Tran AC, Dull TJ, Groopman JE, Capon DJ, Byrn RA, Finer MH (1994) Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84:2878-2889
130. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9-13
131. Rossi JJ (2006) RNAi as a treatment for HIV-1 infection. Biotechniques Suppl: 25-29
132. San Jose E, Munoz-Fernandez MA, Alarcon B (1998) Retroviral vector-mediated expression in primary human T cells of an endoplasmic reticulum-retained CD4 chimera inhibits human immunodeficiency virus type-1 replication. Hum Gene Ther 9:1345-1357
133. Sanhadji K, Leissner P, Firouzi R, Pelloquin F, Kehrli L, Marigliano M, Calenda V, Ottmann M, Tardy JC, Mehtali M, Touraine JL (1997) Experimental gene therapy: the transfer of Tatinducible interferon genes protects human cells against HIV-1 challenge in vitro and in vivo in severe combined immunodeficient mice. Aids 11:977-986
134. Sanhadji K, Grave L, Touraine JL, Leissner P, Rouzioux C, Firouzi R, Kehrli L, Tardy JC, Mehtali M (2000) Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice. Aids 14:2813-2822
135. Sauce D, Bodinier M, Garin M, Petracca B, Tonnelier N, Duperrier A, Melo JV, Apperley JF, Ferrand C, Herve P, Lang F, Tiberghien P, Robinet E (2002) Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culturedependent and selection process-dependent mechanisms. Blood 99:1165-1173
136. Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF,Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE, Rooney CM (2002) Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 100:4059-4066
137. Scaglioni P, Melegari M, Takahashi M, Chowdhury JR, Wands J (1996) Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 24:1010-1017
138. Scaglioni PP,MelegariM,Wands JR (1994) Characterization of hepatitis B virus core mutants that inhibit viral replication. Virology 205:112-120
139. Schambach A, Schiedlmeier B, Kuhlcke K, Verstegen M, Margison GP, Li Z, Kamino K, Bohne J, Alexandrov A, Hermann FG, von Laer D, Baum C (2006) Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus. Gene Ther 13:1037-1047
140. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857-860
141. Seggewiss R, Pittaluga S, Adler RL, Guenaga FJ, Ferguson C, Pilz I, Ryu B, Sorrentino BP, Young WS, Donahue RE, von Kalle C, Nienhuis AW, Dunbar CE (2006) Acute myeloid leukemia associated with retroviral gene transfer to hematopoietic progenitor cells of a rhesus macaque. Blood 107:3865-3867
142. Shaheen F, Duan L, Zhu M, Bagasra O, Pomerantz RJ (1996) Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J Virol 70:3392-3400
143. Shin EC, Protzer U, Untergasser A, Feinstone SM, Rice CM, Hasselschwert D, Rehermann B (2005) Liver-directed gamma interferon gene delivery in chronic hepatitis C. J Virol 79:13412-13420
144. Sommermeyer D, Neudorfer J,WeinholdM, Leisegang M, Engels B, Noessner E, HeemskerkMH, Charo J, Schendel DJ, Blankenstein T, Bernhard H, UckertW(2006) Designer T cells by T cell receptor replacement. Eur J Immunol 36:3052-3059
145. Steinberger P, Andris-Widhopf J, Buhler B, Torbett BE, Barbas CF 3rd (2000) Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci USA 97:805-810
146. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E (1990) Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63:601-608
147. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E (1991) Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 65:6811-6816
148. Tan R, Xu X, Ogg GS, Hansasuta P, Dong T, Rostron T, Luzzi G, Conlon CP, Screaton GR, McMichael AJ, Rowland-Jones S (1999) Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 93:1506-1510
149. Travel JA, Walker RE, Carter C, Natarajan V, Zeng Z, Brechtel C, Jagannatha S, Muul L, Leitman SF, Herpin BR, Stevens RA, Davey RT, Falloon J, Polis MA, Masur H, Metcalf JA, Lane HC, Morgan RA (2001) Preferential survival of syngeneic CD4+ lymphocytes transduced with anti-sense TAR and transdominant Rev protein genes. In: 8th conference on retroviruses and opportunistic infections. pp 125
150. Trono D, Feinberg MB, Baltimore D (1989) HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59:113-120
151. Tung FY, Bowen SW (1998) Targeted inhibition of hepatitis B virus gene expression: a gene therapy approach. Front Biosci 3:a11-a15
152. Ueno T, Fujiwara M, Tomiyama H, Onodera M, Takiguchi M (2004) Reconstitution of anti-HIV effector functions of primary human CD8 T lymphocytes by transfer of HIV-specific alphabeta TCR genes. Eur J Immunol 34:3379-3388
153. Untergasser A, Protzer U (2004) Hepatitis B virus-based vectors allow the elimination of viral gene expression and the insertion of foreign promoters. Hum Gene Ther 15:203-210
154. Uprichard SL, Boyd B, Althage A, Chisari FV (2005) Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci USA 102:773-877
155. Vallanti G, Lupo R, Federico M, Mavilio F, Bovolenta C (2005) T Lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3Gindependent manner. Mol Ther 12:697-706
156. van Lunzen J, Glaunsinger T, Stahmer I, von Baehr V, Baum C, Schilz A, Kuehlcke K, Naundorf S, Martinius H, Hermann F, Giroglou T, Newrzela S, Muller I, Brauer F, Brandenburg G, Alexandrov A, von Laer D (2007) Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 15:1024-1033
157. Volpers C, Kochanek S (2004) Adenoviral vectors for gene transfer and therapy. J Gene Med 6 Suppl 1:S164-S171
158. von Laer D, Kern P, Hufert FT, Schwander S, Dietrich M, Schmitz H (1990) Low percentage of blood and bone marrow monocytes infected with the human immunodeficiency virus (HIV-1) in vivo. Exp Hematol 18:693
159. von Laer D, Hasselmann S, Hasselmann K (2006a) Gene therapy for HIV infection: What does it need to make it work? J Gene Med 8:658-667
160. von Laer D, Hasselmann S, Hasselmann K (2006b) Impact of gene-modified T cells on HIV infection dynamics. J Theor Biol 238:60-77
161. Walker CM, Levy JA (1989) A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunology 66:628-630
162. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, Stevens R, Hazen A, Blaese RM, Chen CC, Leitman SF, Palensky J, Wittes J, Davey RT, Falloon J, Polis MA, Kovacs JA, Broad DF, Levine BL, Roberts MR, Masur H, Lane HC (2000) Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96:467-474
163. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038-1044
164. Weinberg M, PassmanM, Kew M, Arbuthnot P (2000) Hammerhead ribozyme-mediated inhibition of hepatitis B virus X gene expression in cultured cells. J Hepatol 33:142-151
165. Welch PJ, Tritz R, Yei S, Barber J, YuM(1997) Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther 4:736-743
166. Wilson JA, Richardson CD (2005) Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol 79:7050-7058
167. Woffendin C, Ranga U, Yang Z, Xu L, Nabel GJ (1996) Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci USA 93:2889-2894
168. Yamada O, Yu M, Yee JK, Kraus G, Looney D, Wong-Staal F (1994) Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther 1:38-45
169. Yamamoto M, Hayashi N, Takehara T, Ueda K, Mita E, Tatsumi T, Sasaki Y, Kasahara A, Hori M (1999) Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells. Hepatology 30:300-307
170. Yang OO, Tran AC, Kalams SA, Johnson RP, Roberts MR, Walker BD (1997) Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci USA 94:11478-11483
171. Zhang J, Yamada O, Sakamoto T, Yoshida H, Araki H, Murata T, Shimotohno K (2005) Inhibition of hepatitis C virus replication by pol III-directed overexpression of RNA decoys corresponding to stem-loop structures in the NS5B coding region. Virology 342:276-285
172. Zhou P, Goldstein S, Devadas K, Tewari D, Notkins AL (1997) Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: inhibition of mRNA expression. Nat Med 3:659-664
173. Zhu Y, Cullen JM, Aldrich CE, Saputelli J, Miller D, Seeger C, Mason WS, Jilbert AR (2004) Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus. Virology 327:26-40
174. zu Putlitz J,Wieland S, Blum HE,Wands JR (1998) Antisense RNA complementary to hepatitis B virus specifically inhibits viral replication. Gastroenterology 115:702-713